IMRX
NASDAQ · Biotechnology
Immuneering Corp - Class A
$5.02
+0.16 (+3.29%)
Open$4.81
Previous Close$4.86
Day High$5.03
Day Low$4.76
52W High$3.33
52W Low$1.38
Volume—
Avg Volume131.1K
Market Cap318.33M
P/E Ratio26.44
EPS$0.10
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
-29.5% upside
Current
$5.02
$5.02
Target
$3.54
$3.54
$2.50
$3.54 avg
$3.55
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 183.49M | 183.65M | 175.87M |
| Net Income | 12.93M | 12.84M | 10.17M |
| Profit Margin | 7.1% | 7.0% | 5.8% |
| EBITDA | 22.71M | 20.96M | 19.85M |
| Free Cash Flow | 10.88M | 9.00M | 9.93M |
| Rev Growth | -6.7% | +18.5% | +10.5% |
| Debt/Equity | 0.36 | 0.44 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |